Federal Reserve

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Monsoon Floods

Monsoon Floods

Death toll in Uttarakhand monsoon floods crosses 150  Full Article 

Auto Market

Auto Market

Tata Motors upgrades cars as rivals launch new ones.  Full Article 

EU Fines Ranbaxy

EU Fines Ranbaxy

EU fines Ranbaxy, others for blocking cheaper drugs.  Full Article 

Business Optimism

Business Optimism

Asian businesses optimistic; sentiment in India falls.  Full Article 

Financing Trouble

Financing Trouble

U.S. court lets stand Ex-Im Bank loan for Air India.  Full Article 

Euro Economy

Euro Economy

Half-way to lost decade, Europe's growth task as tough as ever.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Lupin plans to launch 3-4 generic drugs in U.S. by end-March

Related Topics

Stocks

   

MUMBAI | Thu Jan 31, 2013 3:06pm IST

MUMBAI (Reuters) - Lupin Ltd(LUPN.NS), India's fourth largest drugmaker by sales, expects to launch three to four new generic drugs in its key U.S. market by March end, its Group President Nilesh Gupta said on Thursday.

The Mumbai-based drugmaker has so far launched six products in this fiscal year in the United States, which generates about 42 percent of its total formulation sales.

The drugmaker earlier reported a forecast-beating 42.6 percent rise in quarterly net profit to 3.35 billion rupees.

(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.